FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)

Drug Safety and Risk Management Advisory Committee (DSaRM)

Holiday Inn Gaithersburg Two Montgomery Village Avenue Gaithersburg, Maryland February 9 & 10, 2006

DRAFT AGENDA

D	٨	1 7	\mathbf{a}	N T	
$\mathbf{\nu}$	\boldsymbol{h}	1	U	ΙN	Ľ

DAY ON	DAY ONE					
8:00 a.m.	Call to Order and Introductions Conflict of Interest Statement	Peter Gross, M.D., Chair (DSaRM) Victoria Ferretti-Aceto, Pharm.D. Executive Secretary Drug Safety and Risk Management Advisory Committee				
8:15 a.m.	Opening Remarks	Dr. Gerald Dal Pan, M.D., Director Office of Drug Safety				
8:30 a.m.	Attention Deficit Hyperactivity Disorder Drugs (ADHD)-Background	Andrew Mosholder, M.D.				
9:00 a.m.	Adverse Cardiovascular Events with ADHD drugs	Kate Gelperin, M.D.				
9:30 a.m.	Update on Feasibility Studies (tentative)	David Graham, M.D.				
10:00 a.m.	Break					
10:15 a.m.	Challenges of Cardiovascular Drug Safety Epidemiology in Post Market Drug Arena	To be announced				
10:45 a.m.	Question and Answer Period					
11:30 a.m.	Lunch					
1:00 p.m.	Open Public Hearing					
2:00 p.m.	Break					
2:15 p.m.	Introduction of Questions	Gerald Dal Pan, M.D.				
2:30 p.m.	Committee Discussion of Questions					
5:00 p.m.	Adjourn					

FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)

Drug Safety and Risk Management Advisory Committee (DSaRM)

Holiday Inn Gaithersburg Two Montgomery Village Avenue Gaithersburg, Maryland February 9 & 10, 2006

DRAFT AGENDA

DAY TWO

8:00 a.m. Call to Order and Introductions Peter Gross, M.D., Chair (DSaRM) Conflict of Interest Statement Victoria Ferretti-Aceto, Pharm.D.

Executive Secretary

Drug Safety and Risk Management Advisory Committee

8:15 a.m. Open Public Hearing

9:15 a.m. General Office of Drug Safety Updates Gerald Dal Pan, M.D.

10:00 a.m. Drug Safety Oversight Board Update Susan Cummins, M.D.

10:30 a.m. Break

10:45 a.m. Risk Management Program, Status

Update-NSAIDs and COX-2 Drugs

Sharon Hertz, M.D.

11:15 a.m. Introduction-Isotretinoin risk

management program

Jill Lindstrom, M.D.

11:30 a.m. Description of iPLEDGE To be announced

1:00 p.m. Adjourn